Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine.

Dogan, Izzet; Paksoy, Nail; Ak, Naziye; Vatansever, Sezai; Saip, Pinar; Aydiner, Adnan

Dogan, Izzet; Paksoy, Nail; Ak, Naziye; Vatansever, Sezai; Saip, Pinar; Aydiner, Adnan.

Afiliação

Dogan I; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Paksoy N; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Ak N; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Vatansever S; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Saip P; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Aydiner A; Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.

Eur J Breast Health ; 19(2): 128-133, 2023 Apr.

Article em En | MEDLINE | ID: mdl-37025570

Palavras-chave

Breast cancer; HER2/neu receptor; capecitabine; lapatinib; metastasis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Eur J Breast Health Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Turquia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google